Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Nab-Paclitaxel in Advanced NSCLC
NCT02967133Phase 2Terminated
- Sponsor
- Alliance Foundation Trials
- Start
- Dec 2016
- Primary completion
- Jan 2018
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Alliance Foundation Trials. Primary endpoint: Progression-Free Survival at 13 months. Started Dec 2016; status: terminated.
02
Drugs
nab-paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02967133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967133.